Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle

New state-of-the-art facility enhances capabilities to advance human-relevant drug discovery and development

Curi Bio, the industry leader in delivering human functional data to the drug discovery community, marked a significant milestone with the official ribbon-cutting ceremony at its new global headquarters located at BioMed Realty’s 201 Elliott Avenue West in Seattle. Held on Thursday, April 3, 2025, the event showcased the company’s newly constructed 13,942-square-foot labs and facility. The new headquarters is designed to support Curi Bio’s growth and continued mission to accelerate innovation in preclinical drug development by unlocking functional human data to inform biopharmaceutical R&D decision making.

The grand opening brought together members of the Curi Bio team, representatives from BioMed Realty, and local media for an afternoon featuring facility tours, demonstrations of Curi Bio’s cutting-edge technologies, and insights shared by company leadership. Guests explored the company’s state-of-the-art laboratory and office spaces built to accommodate growth in critical company functions, including research & development, hardware engineering, cell production, therapeutic assay services, data science, software development, and sales & marketing teams.

“This event is more than a celebration of our new home—it highlights the incredible momentum and collaborative spirit that continues to drive Curi Bio forward,” said Eric Swanson, VP of Operations at Curi Bio. “Our expanded headquarters significantly enhances our capacity to develop and deliver cutting-edge products and services, strengthening our partnerships with customers across many of the world’s largest pharmaceutical companies.”

Located within Seattle’s vibrant life sciences hub, the new headquarters provides Class-A lab space with sweeping views of Puget Sound. The facility was designed with collaboration and employee well-being in mind, featuring modern workspaces, access to green spaces, and proximity to top-tier amenities and transit.

The ribbon-cutting comes at a pivotal time for Curi Bio, as the company continues to expand its comprehensive platforms combining advanced 3D tissue models, biosystems, and advanced analytics. These integrated platforms enable biopharmaceutical researchers to generate functional human data that offers critical insights into drug safety, efficacy, and potency—reducing risk and cost while improving the likelihood of clinical success.

“Our new headquarters represents an exciting next step toward our mission of closing the gap between preclinical models and clinical outcomes,” said Swanson. “We’re excited for the innovations and discoveries ahead in our new space.”

About Curi Bio

Curi Bio unlocks novel workflows and delivers functional human data to inform biopharmaceutical R&D decision making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis, Curi Bio melds functional and analytical assessments for drug safety, efficacy, and potency. By offering leading global pharmaceutical end users an integrated preclinical platform along with highly predictive human stem cell tissue models to generate clinically-relevant data, Curi Bio is bridging the gap between preclinical R&D and clinical outcomes, accelerating the discovery and development of safer, more effective medicines.

For more information, please visit www.curibio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408969541/en/